Cargando…

Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program

OBJECTIVE: The purpose of this study was to identify predictors of incident diabetes during follow-up of nondiabetic patients with chronic heart failure (CHF) in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. RESEARCH DESIGN AND METHODS: A total...

Descripción completa

Detalles Bibliográficos
Autores principales: Preiss, David, Zetterstrand, Sofia, McMurray, John J.V., Östergren, Jan, Michelson, Eric L., Granger, Christopher B., Yusuf, Salim, Swedberg, Karl, Pfeffer, Marc A., Gerstein, Hertzel C., Sattar, Naveed
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2671104/
https://www.ncbi.nlm.nih.gov/pubmed/19196892
http://dx.doi.org/10.2337/dc08-1709
_version_ 1782166348409864192
author Preiss, David
Zetterstrand, Sofia
McMurray, John J.V.
Östergren, Jan
Michelson, Eric L.
Granger, Christopher B.
Yusuf, Salim
Swedberg, Karl
Pfeffer, Marc A.
Gerstein, Hertzel C.
Sattar, Naveed
author_facet Preiss, David
Zetterstrand, Sofia
McMurray, John J.V.
Östergren, Jan
Michelson, Eric L.
Granger, Christopher B.
Yusuf, Salim
Swedberg, Karl
Pfeffer, Marc A.
Gerstein, Hertzel C.
Sattar, Naveed
author_sort Preiss, David
collection PubMed
description OBJECTIVE: The purpose of this study was to identify predictors of incident diabetes during follow-up of nondiabetic patients with chronic heart failure (CHF) in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. RESEARCH DESIGN AND METHODS: A total of 1,620 nondiabetic patients had full baseline datasets. We compared baseline demographic, medication, and laboratory data for patients who did or did not develop diabetes and conducted logistic regression and receiver operator characteristic curve analyses. RESULTS: Over a median period of 2.8 years, 126 of the 1,620 patients (7.8%) developed diabetes. In multiple logistic regression analysis, the following baseline characteristics were independently associated with incident diabetes in decreasing order of significance by stepwise selection: higher A1C (odds ratio [OR] 1.78 per 1 SD increase; P < 0.0001), higher BMI (OR 1.64 per 1 SD increase; P < 0.0001), lipid-lowering therapy (OR 2.05; P = 0.0005), lower serum creatinine concentration (OR 0.68 per 1 SD increase; P = 0.0018), diuretic therapy (OR 4.81; P = 0.003), digoxin therapy (OR 1.65; P = 0.022), higher serum alanine aminotransferase concentration (OR 1.15 per 1 SD increase; P = 0.027), and lower age (OR 0.81 per 1 SD increase; P = 0.048). Using receiver operating characteristic curve analysis, A1C and BMI yielded areas under the curve of 0.723 and 0.712, respectively, increasing to 0.788 when combined. Addition of other variables independently associated with diabetes risk minimally improved prediction of diabetes. CONCLUSIONS: In nondiabetic patients with CHF in CHARM, A1C and BMI were the strongest predictors of the development of diabetes. Other minor predictors in part reflected CHF severity or drug-associated diabetes risk. Identifying patients with CHF at risk of diabetes through simple criteria appears possible and could enable targeted preventative measures.
format Text
id pubmed-2671104
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-26711042010-05-01 Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program Preiss, David Zetterstrand, Sofia McMurray, John J.V. Östergren, Jan Michelson, Eric L. Granger, Christopher B. Yusuf, Salim Swedberg, Karl Pfeffer, Marc A. Gerstein, Hertzel C. Sattar, Naveed Diabetes Care Original Research OBJECTIVE: The purpose of this study was to identify predictors of incident diabetes during follow-up of nondiabetic patients with chronic heart failure (CHF) in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. RESEARCH DESIGN AND METHODS: A total of 1,620 nondiabetic patients had full baseline datasets. We compared baseline demographic, medication, and laboratory data for patients who did or did not develop diabetes and conducted logistic regression and receiver operator characteristic curve analyses. RESULTS: Over a median period of 2.8 years, 126 of the 1,620 patients (7.8%) developed diabetes. In multiple logistic regression analysis, the following baseline characteristics were independently associated with incident diabetes in decreasing order of significance by stepwise selection: higher A1C (odds ratio [OR] 1.78 per 1 SD increase; P < 0.0001), higher BMI (OR 1.64 per 1 SD increase; P < 0.0001), lipid-lowering therapy (OR 2.05; P = 0.0005), lower serum creatinine concentration (OR 0.68 per 1 SD increase; P = 0.0018), diuretic therapy (OR 4.81; P = 0.003), digoxin therapy (OR 1.65; P = 0.022), higher serum alanine aminotransferase concentration (OR 1.15 per 1 SD increase; P = 0.027), and lower age (OR 0.81 per 1 SD increase; P = 0.048). Using receiver operating characteristic curve analysis, A1C and BMI yielded areas under the curve of 0.723 and 0.712, respectively, increasing to 0.788 when combined. Addition of other variables independently associated with diabetes risk minimally improved prediction of diabetes. CONCLUSIONS: In nondiabetic patients with CHF in CHARM, A1C and BMI were the strongest predictors of the development of diabetes. Other minor predictors in part reflected CHF severity or drug-associated diabetes risk. Identifying patients with CHF at risk of diabetes through simple criteria appears possible and could enable targeted preventative measures. American Diabetes Association 2009-05 2009-02-05 /pmc/articles/PMC2671104/ /pubmed/19196892 http://dx.doi.org/10.2337/dc08-1709 Text en © 2009 by the American Diabetes Association. https://creativecommons.org/licenses/by-nc-nd/3.0/Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ (https://creativecommons.org/licenses/by-nc-nd/3.0/) for details.
spellingShingle Original Research
Preiss, David
Zetterstrand, Sofia
McMurray, John J.V.
Östergren, Jan
Michelson, Eric L.
Granger, Christopher B.
Yusuf, Salim
Swedberg, Karl
Pfeffer, Marc A.
Gerstein, Hertzel C.
Sattar, Naveed
Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program
title Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program
title_full Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program
title_fullStr Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program
title_full_unstemmed Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program
title_short Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program
title_sort predictors of development of diabetes in patients with chronic heart failure in the candesartan in heart failure assessment of reduction in mortality and morbidity (charm) program
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2671104/
https://www.ncbi.nlm.nih.gov/pubmed/19196892
http://dx.doi.org/10.2337/dc08-1709
work_keys_str_mv AT preissdavid predictorsofdevelopmentofdiabetesinpatientswithchronicheartfailureinthecandesartaninheartfailureassessmentofreductioninmortalityandmorbiditycharmprogram
AT zetterstrandsofia predictorsofdevelopmentofdiabetesinpatientswithchronicheartfailureinthecandesartaninheartfailureassessmentofreductioninmortalityandmorbiditycharmprogram
AT mcmurrayjohnjv predictorsofdevelopmentofdiabetesinpatientswithchronicheartfailureinthecandesartaninheartfailureassessmentofreductioninmortalityandmorbiditycharmprogram
AT ostergrenjan predictorsofdevelopmentofdiabetesinpatientswithchronicheartfailureinthecandesartaninheartfailureassessmentofreductioninmortalityandmorbiditycharmprogram
AT michelsonericl predictorsofdevelopmentofdiabetesinpatientswithchronicheartfailureinthecandesartaninheartfailureassessmentofreductioninmortalityandmorbiditycharmprogram
AT grangerchristopherb predictorsofdevelopmentofdiabetesinpatientswithchronicheartfailureinthecandesartaninheartfailureassessmentofreductioninmortalityandmorbiditycharmprogram
AT yusufsalim predictorsofdevelopmentofdiabetesinpatientswithchronicheartfailureinthecandesartaninheartfailureassessmentofreductioninmortalityandmorbiditycharmprogram
AT swedbergkarl predictorsofdevelopmentofdiabetesinpatientswithchronicheartfailureinthecandesartaninheartfailureassessmentofreductioninmortalityandmorbiditycharmprogram
AT pfeffermarca predictorsofdevelopmentofdiabetesinpatientswithchronicheartfailureinthecandesartaninheartfailureassessmentofreductioninmortalityandmorbiditycharmprogram
AT gersteinhertzelc predictorsofdevelopmentofdiabetesinpatientswithchronicheartfailureinthecandesartaninheartfailureassessmentofreductioninmortalityandmorbiditycharmprogram
AT sattarnaveed predictorsofdevelopmentofdiabetesinpatientswithchronicheartfailureinthecandesartaninheartfailureassessmentofreductioninmortalityandmorbiditycharmprogram
AT predictorsofdevelopmentofdiabetesinpatientswithchronicheartfailureinthecandesartaninheartfailureassessmentofreductioninmortalityandmorbiditycharmprogram